Cargando…

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a refractory malignant tumor with poor prognosis, limited chemotherapeutic efficacy, and only about 5% of 5‐year survival rate. We generated a dual‐targeting ligand‐based lidamycin (DTLL) to investigate its efficacy against pancreatic cancer after preparing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Rui, Song, Wenping, Ye, Cheng, Liu, Xiujun, Li, Liang, Li, Yi, Yao, Hongjuan, Zhou, Xiaofei, Shao, Rongguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382721/ https://www.ncbi.nlm.nih.gov/pubmed/30681288 http://dx.doi.org/10.1002/cam4.1974

Ejemplares similares

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
por: Yao, Hongjuan, et al.
Publicado: (2022)

Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK‐mTOR signaling
por: Xie, Gangyin, et al.
Publicado: (2020)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
por: Liu, Jingjing, et al.
Publicado: (2019)

mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development
por: Feng, Jing, et al.
Publicado: (2020)

Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
por: Zhang, Deyi, et al.
Publicado: (2021)

MicroRNA‐221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling
por: Yin, Yingchun, et al.
Publicado: (2020)

Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk
por: Qi, Guang-Hui, et al.
Publicado: (2020)

Metformin induces degradation of mTOR protein in breast cancer cells
por: Alalem, Mohamed, et al.
Publicado: (2016)

LncRNA‐LOC101928316 contributes to gastric cancer progression through regulating PI3K‐Akt‐mTOR signaling pathway
por: Li, Chengyun, et al.
Publicado: (2019)

STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch–mTOR signaling pathway
por: Liu, Liheng, et al.
Publicado: (2020)

miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway
por: Duan, Jinjin, et al.
Publicado: (2021)

Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
por: Cai, Fangzhen, et al.
Publicado: (2020)

SLC39A7, regulated by miR-139-5p, induces cell proliferation, migration and inhibits apoptosis in gastric cancer via Akt/mTOR signaling pathway
por: Zhang, Yanting, et al.
Publicado: (2020)

LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/β-catenin signaling pathways
por: Liu, Zhihui, et al.
Publicado: (2020)

MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells
por: Tong, Gangling, et al.
Publicado: (2019)

The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma
por: Zhang, Xuan, et al.
Publicado: (2017)

Puerarin 6″‐O‐xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR
por: Li, Long, et al.
Publicado: (2020)

Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
por: Chen, Yonghong, et al.
Publicado: (2023)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
por: Farmaki, Elena, et al.
Publicado: (2023)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway
por: Jiang, Hao, et al.
Publicado: (2019)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Mechanism of Autophagy Regulation in MPTP-Induced PD Mice via the mTOR Signaling Pathway by Echinacoside
por: Zhang, Zhen-Nian, et al.
Publicado: (2021)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery
por: Tao, Qiangqiang, et al.
Publicado: (2020)

Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway
por: Liu, Mian, et al.
Publicado: (2022)

EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
por: James, Roshan, et al.
Publicado: (2012)

Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells
por: Suzuki, Kenjiro, et al.
Publicado: (2013)

A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells
por: Yao, Hongjuan, et al.
Publicado: (2020)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Up‐regulation of miR‐497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl‐2
por: Zhu, Danhua, et al.
Publicado: (2017)

miR‐155‐regulated mTOR and Toll‐like receptor 5 in gastric diffuse large B‐cell lymphoma
por: Huang, Wei‐Ting, et al.
Publicado: (2021)

Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation
por: Park, Hae J, et al.
Publicado: (2022)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

ZDHHC2-Mediated AGK Palmitoylation Activates AKT–mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma
por: Sun, Yan, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djv3usae0buo59oe5jbdddkhj3